1292307-06-2

Usage

Uses

Used in Pharmaceutical Industry:
(1S,3R)-methyl 3-hydroxycyclopentanecarboxylate is used as a synthetic intermediate for the development of pharmaceutical products. Its unique stereochemistry allows for the creation of enantiomerically pure compounds, which are crucial for the efficacy and safety of many drugs. This intermediate is particularly valuable in the synthesis of chiral molecules, which have different biological activities based on their spatial arrangement.
Used in Drug Synthesis:
(1S,3R)-methyl 3-hydroxycyclopentanecarboxylate is used as a key building block in the synthesis of various drugs. Its presence in the molecular structure can influence the drug's pharmacokinetics, pharmacodynamics, and overall therapeutic effect. By incorporating this intermediate into drug molecules, chemists can design and develop new medications with improved properties, such as enhanced potency, selectivity, and reduced side effects.
Used in Chiral Chemistry Research:
(1S,3R)-methyl 3-hydroxycyclopentanecarboxylate is also used as a research tool in the field of chiral chemistry. It serves as a model compound for studying the effects of stereochemistry on molecular interactions, such as binding to biological targets, enzyme inhibition, and receptor activation. This research can lead to a better understanding of the role of chirality in drug action and the development of more effective and selective therapeutic agents.

Upstream product

• 58101-60-3 methyl cyclopent-3-ene-1-carboxylate 
• 98-78-2 3-Oxo-cyclopentanecarboxylic acid 
• 132076-27-8 (R)-methyl 3-oxocyclopentanecarboxylate 
• 13012-38-9 (1R)-3-oxocyclopentane-1-carboxylic acid 
• 67-56-1 methanol 
• 32811-75-9 methyl 3-oxocyclopentane-1-carboxylate 
• 86885-57-6 rac-methyl (1R,5S)-6-oxabicyclo[3.1.0]hexane-3-carboxylate 

Downstream Products

• 109646-10-8 (+/-)-cis-3-methoxy-cyclopentanecarboxylic acid p-toluidide 

Relevant academic research and scientific papers

Horse Liver Alcohol Dehydrogenase-catalyzed Enantioselective Reduction of Cyclic Ketones: The Effect of the Hydrophobic Side Chain of the Substrate on the Stereoselectivity of the Reaction

Horse liver alcohol dehydrogenase (HLADH)-catalyzed enantioselective reductions of alkyl 3-oxocyclopentanecarboxylates, endo-5-acyloxybicycloheptan-2-ones and exo-5-acyloxybicycloheptan-2-ones gave the corresponding homochiral alcohols and ketones and the interaction between the hydrophobic side chain of the substrate and the hydrophobic zone in the active site played an important role in the specificity of the reduction.The stereoselectivities of the reactions were interpreted on the basis of the cubic space section model and a new rule, which contributes to development of a specificity analysis on the basis of the model, is introduced.

5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

Provided are 5-(pyridin-3-yl) oxazole compounds, the compositions comprising these compounds and the uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME

Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically accept

Synthesizing method of cis-3-hydroxy-cyclopentane carboxylate or cyclohexane carboxylate and derivative thereof

The invention discloses a synthesizing method of cis-3-hydroxy-cyclopentane carboxylate or cyclohexane carboxylate and a derivative thereof. The method includes: a compound III serving as the raw material and hydrogen are subjected to one-step ring-opening reaction in a solvent in the presence of alkali and a catalyst to prepare the cis-3-hydroxy-cyclopentane carboxylate or cyclohexane carboxylateand the derivative thereof. The method is simple and practicable, high in product yield and suitable for large-scale production.

N-substituted imidazole carboxylate compounds, and preparation method and medical application thereof

The invention relates to a compound represented as a general formula (I) or a stereoisomer, solvate, pharmaceutically acceptable salt or eutectic crystal of the compound, and a composition, preparation method and medical application of the compound, the stereoisomer, the solvate, the pharmaceutically acceptable salt and the eutectic crystal. The general formula (I) is shown as follows, and the definition of each substituent group is consistent as in the specification.

ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF

The present invention relates to novel adenine based inhibitors of adenylyl cyclase of the formula: wherein X, L, R1, R2, R5 are those defined herein. Compounds of the present invention are useful to treat cardiovascular diseases. The present invention also relates to a method of preventing heart failure by administering an effective amount of compound according to the invention following vascular injury and reperfusion therapy.

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS

Compounds, pharmaceutical compositions, methods and kits are described for treating or preventing neurodegenerative diseases such as Alzheimer's disease.

Glutaminase inhibitors as well as compositions and applications thereof

The invention provides a series of heterocyclic compounds expressed in a formula I. The compound comprises glutaminase inhibition activity, and can be used for treating diseases and symptoms related to dysfunction of glutaminase or raising activity of glutaminase.

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease.

NOVEL CYCLOPENTANE DERIVATIVES

The invention relates to a compound of formula (I) wherein A1 and R1 to R5 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.